Management of refractory Mycoplasma pneumoniae pneumonia: Utility of measuring serum lactate dehydrogenase level

Journal of Infection and Chemotherapy

Volumn 20, Issue 4, 2014, Pages 270-273

  Inamura, Norikazu ^a   Miyashita, Naoyuki ^a   Hasegawa, Shunji ^b   Kato, Atsushi ^a   Fukuda, Yoko ^a   Saitoh, Aki ^a   Kondo, Eisuke ^a   Teranishi, Hideto ^a   Wakabayashi, Tokio ^a   Akaike, Hiroto ^a   Tanaka, Takaaki ^a   Ogita, Satoko ^a   Nakano, Takashi ^a   Terada, Kihei ^a   Ouchi, Kazunobu ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell mediated immune response; Corticosteroid; Macrolide resistant; Mycoplasma pneumoniae; Pneumonia; Refractory

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZITHROMYCIN; CEFDITOREN PIVOXIL; CLARITHROMYCIN; CLINDAMYCIN; INTERLEUKIN 18; LACTATE DEHYDROGENASE; MACROLIDE; METHYLPREDNISOLONE; MINOCYCLINE; QUINOLONE DERIVATIVE; RNA 23S; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DETERIORATION; DRUG PULSE THERAPY; FEMALE; FEVER; HUMAN; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MYCOPLASMA PNEUMONIA; POINT MUTATION; POLYMERASE CHAIN REACTION; REFRACTORY MYCOPLASMA PNEUMONIAE PNEUMONIA; TREATMENT RESPONSE; ADOLESCENT; BLOOD; COHORT ANALYSIS; DRUG EFFECTS; GENETICS; INFANT; JAPAN; MICROBIOLOGY; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; INTERLEUKIN-18; JAPAN; L-LACTATE DEHYDROGENASE; MALE; METHYLPREDNISOLONE; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; TREATMENT OUTCOME;

EID: 84903742749     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2014.01.001     Document Type: Article

References (16)

1. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004;217: 697-728.
2. Lee K-Y, Lee H-S, Hong J-H, Lee M-H, Lee J-S, Burgner D, et al. Role of predonisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2006;41: 263-8.
3. Miyashita N, Obase Y, Ouchi K, Kawasaki K, Kawai Y, Kobashi Y, et al. Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. J Med Microbiol 2007;56: 1625-9.
4. Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T. Methylpredonisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect 2008;57: 223-8.
5. Lu A, Wang L, Zhang X, Zhang M. Combined treatment for child refractory Mycoplasma pneumoniae pneumonia with ciproxacin and glucocorticoid. Pediatr Pulmonol 2011;46: 1093-7.
6. Luo Z, Luo J, Liu E, Xu X, Liu Y, Zeng F, et al. Effects of prednisolone on Mycoplasma pneumoniae pneumonia in chirdren. Pediatr Pulmonol 2013 Feb 8. http://dx.doi.org/10.1002/ppul.22752 [Epub ahead of print].
7. Radisic M, Torn A, Gutierrez P, Defranchi HA, Pardo P. Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin Infect Dis 2000;31: 1507-11.
8. Narita M, Tanaka H, Abe S, Yamada S, Kubota M, Togashi T. Close association between pulmonary disease manifestation in Mycoplasma pneumoniae infection and enhanced local production of interleukin-18 in the lung, independent of gamma interferon. Clin Diagn Lab Immunol 2000;7: 909-14.
9. Narita M, Tanaka H, Yamada S, Abe S, Ariga T, Sakiyama Y. Significant role of interleukin-8 in pathogenesis of pulmonary disease due to Mycoplasma pneumoniae infection. Clin Diagn Lab Immunol 2001;8: 1028-130.
10. Tanaka H, Narita M, Teramoto S, Saikai T, Oashi K, Igarashi T, et al. Role of interleukin-18 and type I cytokines in the development of Mycoplasma pneumoniae pneumonia in adults. Chest 2002;121: 1493-7.
11. Oishi T, Narita M, Matsui K, Shirai T, Matsuo M, Negishi J, et al. Clinical implications of interleukin-18 levels in pediatric patients with Mycoplasma pneumoniae pneumonia. J Infect Chemother 2011;17: 803-6.
12. Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, et al. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis 2008;198: 1180-8.
13. Miyashita N, Akaike H, Teranishi H, Ouchi K, Okimoto N. Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility and therapeutic efficacy. Antimicrob Agents Chemother 2013;57: 5181-5.
14. Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. Antimicrob Agents Chemother 2013;57: 2252-8.
15. The Committee for the Guidelines in Management of Respiratory Infectious Diseases in Children. Guidelines for the management of respiratory infectious diseases in children in Japan 2011. In: Ouchi K, Kurosaki T, Okada K, editors. Japanese society of pediatric pulmonology/Japanese society for pediatric infectious diseases (Tokyo) 2011.
16. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143: 29-36. Technology Technology